A common mechanism of clinical HIV-1 resistance to the CCR5 antagonist maraviroc despite divergent resistance levels and lack of common gp120 resistance mutations
about
HIV Genome-Wide Protein Associations: a Review of 30 Years of ResearchMaraviroc: a review of its use in HIV infection and beyondHIV-1 envelope-receptor interactions required for macrophage infection and implications for current HIV-1 cure strategiesHIV-1 gp120 as a therapeutic target: navigating a moving labyrinthDefining the fitness of HIV-1 isolates with dual/mixed co-receptor usagei-bodies, Human Single Domain Antibodies That Antagonize Chemokine Receptor CXCR4.A single-residue change in the HIV-1 V3 loop associated with maraviroc resistance impairs CCR5 binding affinity while increasing replicative capacity.The maraviroc expanded access program - safety and efficacy data from an open-label study.Distinct HIV-1 entry phenotypes are associated with transmission, subtype specificity, and resistance to broadly neutralizing antibodies.Site-selective solid-phase synthesis of a CCR5 sulfopeptide library to interrogate HIV binding and entry.The discovery of allyltyrosine based tripeptides as selective inhibitors of the HIV-1 integrase strand-transfer reaction.Short Communication: HIV-1 Variants That Use Mouse CCR5 Reveal Critical Interactions of gp120's V3 Crown with CCR5 Extracellular Loop 1Genotypic analysis of the V3 region of HIV from virologic nonresponders to maraviroc-containing regimens reveals distinct patterns of failure.Frequency and Env determinants of HIV-1 subtype C strains from antiretroviral therapy-naive subjects that display incomplete inhibition by maraviroc.Driving HIV-1 into a Vulnerable Corner by Taking Advantage of Viral Adaptation and Evolution.Clinical relevance of target identity and biology: implications for drug discovery and development.Understanding and applying tyrosine biochemical diversity.CCR5 receptor antagonists in preclinical to phase II clinical development for treatment of HIV.Quantifying CD4/CCR5 Usage Efficiency of HIV-1 Env Using the Affinofile System.Incompatible Natures of the HIV-1 Envelope in Resistance to the CCR5 Antagonist Cenicriviroc and to Neutralizing Antibodies.Preclinical discovery and development of maraviroc for the treatment of HIV.HIV-1 Group O Genotypes and Phenotypes: Relationship to Fitness and Susceptibility to Antiretroviral Drugs.Combination of the CCL5-derived peptide R4.0 with different HIV-1 blockers reveals wide target compatibility and synergic cobinding to CCR5CSF inflammatory markers and neurocognitive function after addition of maraviroc to monotherapy darunavir/ritonavir in stable HIV patients: the CINAMMON study.Phenotypic co-receptor tropism and Maraviroc sensitivity in HIV-1 subtype C from East Africa.Mapping Interaction Sites on Human Chemokine Receptors by Deep Mutational Scanning.
P2860
Q26746070-EA8651A7-68FA-431A-AE22-0BF517C53C1FQ26778504-2E9B804A-82EE-4515-AD3E-F0C63CAE0D02Q26825087-BC288BDC-CF0D-4029-AEC8-7CC5B767052FQ28086826-2CACCD10-5421-4EA2-BA79-DAED85E85CF0Q30278577-739D5998-5C27-4227-8F7E-8A4D05586913Q30386356-C9367FCF-78FF-45D5-8FA5-C4F274B246BFQ30654651-DB23D01A-C48A-465A-A035-B49C02C9A135Q30911112-447BACFC-F3FB-424D-A972-3052E12C0211Q34503200-B8CAEE56-1EDE-42B1-BF68-682DA53AB4A8Q35194597-0D1EC281-6D61-4F02-A018-4B866A2A62DBQ36029560-C59B1ED8-AFB4-4F7D-8D00-C0359B0B4530Q36078450-1A62A3B0-19D9-42DC-A4B5-33425550A618Q37335890-B8191D92-D3E7-4DC6-B2F7-2970F064AFCBQ37390786-AD853231-1A01-4A19-8458-3CBFEB12B00AQ37703084-4DF66D3E-91DC-4E4A-87C8-76B411F18742Q38147723-C3256421-32DF-44DF-A401-305C3A5E0CBEQ38195522-F993B142-F918-4D9C-8256-CA8E9433683AQ38803127-68C39579-79A6-40A5-B818-BE33E28B1F94Q38808224-189785AE-23D6-401C-A3D3-D519D4D9FAB0Q38822845-724E3700-31A4-446A-A5AF-7A99E098366CQ39556338-87ACDCCD-B460-4AE1-A78F-54FDD8C10370Q40797960-EB464C0E-D8E8-4A07-B901-4CB8586690AAQ41897622-B8089A62-CC3A-441C-93DE-66123CCFC8ADQ47894419-E3E78545-7086-492C-8C6F-B8A852DAA242Q48102649-04C121DE-BA5F-49EC-95DA-E069693D17AFQ52573419-85B684F2-AAEB-472D-9520-2385C721849F
P2860
A common mechanism of clinical HIV-1 resistance to the CCR5 antagonist maraviroc despite divergent resistance levels and lack of common gp120 resistance mutations
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
2013年论文
@zh
2013年论文
@zh-cn
name
A common mechanism of clinical ...... mon gp120 resistance mutations
@en
type
label
A common mechanism of clinical ...... mon gp120 resistance mutations
@en
prefLabel
A common mechanism of clinical ...... mon gp120 resistance mutations
@en
P2093
P2860
P50
P356
P1433
P1476
A common mechanism of clinical ...... mon gp120 resistance mutations
@en
P2093
Anne Ellett
Becky Jubb
Hamid Salimi
Helena Zappi
Kelechi Chikere
Melissa J Churchill
Mike Westby
Miranda S Moore
Nicholas E Webb
Paul R Gorry
P2860
P2888
P356
10.1186/1742-4690-10-43
P50
P577
2013-04-20T00:00:00Z
P5875
P6179
1044358802